Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is app...

Full description

Bibliographic Details
Main Authors: Ernesto Rossi, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Tommaso Dosa, Maurizio Martini, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Giovanni Schinzari
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
BRAF
MEK
target therapy
conjunctival
melanoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00232/full
Description
Summary:Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
ISSN:2234-943X

Similar Items